A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Camizestrant in Post-menopausal Female Subjects

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2022-502277-41-00

Acronym

D8532C00002

Enrollment

Registered

2023-05-19

Start date

2023-06-05

Completion date

2024-02-22

Last updated

2024-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

moderate or severe hepatic impairment

None listed

Sex/Gender

All

Age

18 Years to No maximum

Bulgaria, Slovakia

None listed

Source: EU CTIS · Data processed: Feb 4, 2026